Drug & intervention
sevelamer
RxCUI 214824
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Sevelamer
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
3 shownGLP-1-mediated Gluco-metabolic Effects of Bile Acid SequestrationNCT03739268 · 2018-09-01
COMPLETEDEffect of Bile Acid Secretion and Sequestration on GLP-1 SecretionNCT02445508 · 2015-05-01
COMPLETEDCARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis PatientsNCT00211939 · 2005-01-01
COMPLETEDConditions being studied
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.